Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region

International Journal of Gynecological Pathology

Volumn 25, Issue 1, 2006, Pages 70-76

  Nakayama, Masato ^a   Mitsuhashi, Tomoko ^b   Shimizu, Yoshihiko ^a   Ban, Shinichi ^a   Ogawa, Fumihiro ^a   Ishihara, Osamu ^a   Shimizu, Michio ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

c kit aberrations; Carcinosarcoma; Gynecologic region; Imatinib; Immunohistochemistry; KIT; Sarcoma

Indexed keywords

IMATINIB; MEMBRANE RECEPTOR; POLYCLONAL ANTIBODY; STEM CELL FACTOR RECEPTOR; DNA; TUMOR MARKER;

ARTICLE; CANCER SURGERY; CARCINOSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM SARCOMA; EXON; FEMALE; FEMALE GENITAL SYSTEM; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; UTERUS SARCOMA; VAGINA CANCER; FEMALE GENITAL TRACT TUMOR; METABOLISM; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; SARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 33644829020     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000183047.45459.36     Document Type: Article

References (27)

1. Morrow CP, Curtin JP. Uterine sarcomas and related tumors. In: Morrow CP, Curtin JP, eds. Synopsis of Gynecologic Oncology. 5th ed. Churchill Livingstone, Edinburgh, Scotland, 1998:187-206.
2. Nordal RR, Thoreson SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 1997;33:907-11.
3. Knocke TH, Kucera H, Dorfler D, et al. Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 1998;83:1972-9.
4. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effects of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal tumor. N Engl J Med 2001;344:1052-6.
5. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
6. Savage DG, Antman KH. Imatinib mesylate- a new oral targeted therapy. N Engl J Med 2002;346:683-93.
7. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Am J Pathol 2000;156:791-5.
8. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal tumor. J Clin Oncol 2003;21:4342-9.
9. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet 2004;364:1134-7.
10. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-5.
11. Longley BJ, Reguera MJ, Ma Y. Classes of c-kit activating mutation: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res 2001;25:571-6.
12. Leath CA 3rd, Straughn JM Jr, Conner MG, et al. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med 2004;49:71-5.
13. Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol 2003;22:181-4.
14. Winter WE 3rd, Seidman JD, Krivak TC, et al. Clinicopathologic analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol 2003;91:3-8.
15. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT(CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-93.
16. Oliva E, Young RH, Amin MB, et al. An Immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002;26:403-12.
17. Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol 1990;21:607-12.
18. Yamaguch U, Hasegawa T, Masuda T, et al. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch 2004;445:142-50.
19. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
20. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and Imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;23:4342-9.
21. Rushing RS, Shajahan S, Chendil D, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-kit. Gynecol Oncol 2003;91:9-14.
22. Leong ASY, Cooper K, Leong FJWM. Manual of Diagnostic Antibodies for Immunohistology. 2nd ed. London: Greenwich Medical Media, 2003.
23. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44.
24. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-4.
25. Tian Q, Frierson HF, Kruystal GW, et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:1643-7.
26. Dewar AL, Zannettino AC, Hughes TP, et al. Inhibition of c-fms by Imatinib: expression the spectrum of treatment. Cell Cycle 2005;4:851-3.
27. Holdhoff M, Kreuzer KA, Appelt C, et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 2005;34:181-5.